

CITATION REPORT

List of articles citing

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-201

DOI: 10.1111/liv.13548

Liver International, 2018, 38, 532-541.

Source: <https://exaly.com/paper-pdf/69776761/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	The IBD and PSC Phenotypes of PSC-IBD. <i>Current Gastroenterology Reports</i> , 2018 , 20, 16	5	32
50	Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. <i>PLoS ONE</i> , 2018 , 13, e0209352	3.7	14
49	Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. <i>Journal of Liver</i> , 2018 , 7,	2	5
48	Primary sclerosing cholangitis in children versus adults: lessons for the clinic. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 1025-1032	4.2	7
47	Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-Liver interrelation. <i>Gastroenterology & Hepatology (English Edition)</i> , 2019 , 42, 316-325	0.1	4
46	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 1492-1500	1.5	24
45	The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019 , 2, S73-S80	0.5	39
44	Cholangiocarcinoma: Epidemiology and risk factors. <i>Liver International</i> , 2019 , 39 Suppl 1, 19-31	7.9	181
43	Systematic review with meta-analysis: Chromoendoscopy versus white light endoscopy in detection of dysplasia in patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2019 , 20, 206-214	2.3	5
42	Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. <i>Frontiers in Medicine</i> , 2019 , 6, 293	4.9	19
41	Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 370-379	6.9	38
40	Extrahepatic autoimmunity in autoimmune liver disease. <i>European Journal of Internal Medicine</i> , 2019 , 59, 1-7	3.9	14
39	Associations Between Drug Exposure and Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1244-1245	6.9	5
38	Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 74-81	2.4	18
37	Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing Cholangitis Consortium. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020 , 71, 459-464	2.8	2
36	Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Translational Autoimmunity</i> , 2020 , 3, 100054	4.1	1
35	The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. <i>JGH Open</i> , 2020 , 4, 1128-1134	1.8	1

34	Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1. <i>Therapeutic Advances in Gastroenterology</i> , 2020 , 13, 1756284820927292	4.7	10
33	Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 927-939	4.5	6
32	Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211004839	4.7	0
31	Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Clinical Gastroenterology</i> , 2021 , 115-136	0	0
30	Pancreatic Disorders in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	2
29	Sclerosing cholangitis and inflammatory bowel disease: which comes first?. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2021 , 66, 39-46	0.4	2
28	Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1959-1973	1.5	3
27	Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. <i>Gastroenterologiya Y Hepatologiya</i> , 2021 ,	0.9	1
26	Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	7
25	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. <i>Gut</i> , 2021 , 70, 1989-2003	3.2	7
24	Increased risk of cancer in patients with primary sclerosing cholangitis. <i>Hepatology International</i> , 2021 , 15, 1174-1182	8.8	1
23	Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , 2021 ,	5.3	1
22	Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021 , 2021, 9936932	2.8	0
21	Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. <i>Gastroenterologiya Y Hepatologiya</i> , 2019 , 42, 316-325	0.9	8
20	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. <i>Gastroenterology</i> , 2020 , 159, 915-928	13.3	37
19	Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. <i>Annals of Gastroenterology</i> , 2019 , 32, 124-133	2.2	22
18	Colorectal Cancer Risk and Screening in Geriatric Patients. 2019 , 131-163		
17	Ustekinumab in patients with Crohn's disease with extraintestinal manifestations (psoriasis). <i>Meditsinskiy Sovet</i> , 2020 , 121-126	0.4	1

16	Liver involvement in inflammatory bowel disease: What should the clinician know?. <i>World Journal of Hepatology</i> , 2021 , 13, 1534-1551	3.4	0
15	Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.. <i>United European Gastroenterology Journal</i> , 2022 ,	5.3	1
14	Epigenetic Signatures Discriminate Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis From Patients With Ulcerative Colitis.. <i>Frontiers in Immunology</i> , 2022 , 13, 840935	8.4	0
13	Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease.. <i>Scandinavian Journal of Gastroenterology</i> , 2021 , 1-8	2.4	
12	Solid extraintestinal malignancies in patients with inflammatory bowel disease.. <i>World Journal of Gastrointestinal Oncology</i> , 2021 , 13, 1956-1980	3.4	0
11	Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. <i>Gastroenterologia Y Hepatologia (English Edition)</i> , 2022 , 45, 83-90	0.1	
10	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , 2022 ,	13.4	4
9	A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases.		0
8	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022 , 29, 6091-6114		0
7	Surveillance for cholangiocarcinoma in patients with primary sclerosing cholangitis: Can we be more proactive?. <i>flgastro-2022-102172</i>		
6	AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.		4
5	Mortality in patients with Inflammatory Bowel Disease: Results from 30 years of follow-up in a Norwegian inception cohort (the IBSEN study).		1
4	The microbiota and the gut-liver axis in primary sclerosing cholangitis.		0
3	Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy.		0
2	Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology. 29, 272-285		0
1	What Do NAFLD, Liver Fibrosis, and Inflammatory Bowel Disease Have in Common? Review of the Current Literature. 2023 , 13, 378		0